Jordi Ponce
Bellvitge University Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jordi Ponce.
International Journal of Gynecological Cancer | 2015
Delphine Hudry; Sarfraz Ahmad; Vanna Zanagnolo; Fabrice Narducci; Maxime Fastrez; Jordi Ponce; Elisabeth von Tucher; Fabrice Lecuru; Vanessa Conri; Pierre Leguevaque; Frédéric Goffin; Robert W. Holloway; Eric Lambaudie
Objectives The aim of this study was to evaluate perioperative outcomes of robotic-assisted laparoscopic para-aortic lymphadenectomy (PAL) in patients with gynecologic cancers during the learning phases of robotic surgery programs and to compare results of extraperitoneal versus transperitoneal approaches of PAL. Materials and Methods This study is a retrospective multicentric study of patients who underwent robotically assisted laparoscopic PAL (N = 487). Eleven European centers and 1 US center participated in the study. Abstracted data included age, body mass index, indication, type of surgical approach (transperitoneal or extraperitoneal), associated surgical procedures, operative time, estimated blood loss, lymph node count, hospital length of stay (LOS), and complications. Para-aortic lymphadenectomy was performed by an extraperitoneal approach in 58 cases (12%) and transperitoneal in 429 cases (88%). Results The mean (SD) para-aortic lymph node count was 12.6 (8.1), operative time was 217 (85) minutes, estimated blood loss was 105 (110) mL, and LOS was 2.8 (3.2) days. Four (0.8%) conversions to open and 2 (0.4%) conversions to laparoscopy were described. There were 32 lymphocysts (6.6%), 3 deep venous thromboses (0.6%), and 10 transfusions (2.1%). For transperitoneal approach, the average number of lymph nodes removed was higher in isolated PAL group than the hysterectomy combined group (report node counts 95% confidence interval, −7.29 to −3.52, P = 1.5 × 10−6). For isolated PAL, the LOS was shorter in the extraperitoneal group than in the transperitoneal group (report data 95% CI, −1.35 to −0.35, P = 0.001). Conclusions Robotic-assisted PAL seems safe and feasible. More lymph nodes were removed during an isolated transperitoneal PAL dissection compared with a combined procedure with hysterectomy. Extraperitoneal approach seems attractive relative to transperitoneal dissection, but the superiority of one or the other way is not demonstrated by our study.
Purinergic Signalling | 2013
Elisabet Aliagas; August Vidal; Benjamín Torrejón-Escribano; Maria del Rosario Taco; Jordi Ponce; Inmaculada Gómez de Aranda; Jean Sévigny; Enric Condom; Mireia Martín-Satué
Extracellular ATP and its hydrolysis product, adenosine, acting through specific receptors collectively named purinergic receptors, regulate female fertility by influencing the endometrial fluid microenvironment. There are four major groups of ecto-nucleotidases that control the levels of extracellular ATP and adenosine and thus their availability at purinergic receptors: ecto-nucleoside triphosphate diphosphohydrolases (E-NTPDases), ecto-nucleotide pyrophosphatase/phospho-diesterases (E-NPPs), ecto-5′-nucleotidase (5′NT), and alkaline phosphatases (APs). The aim of the present work is to characterize the expression and distribution of ecto-nucleotidases in human endometrium along the menstrual cycle and after menopause, to evaluate their potential utility as fertility markers. We examined proliferative, secretory and atrophic endometria from women without endometrial pathology undergoing hysterectomy. We show that the ecto-nucleotidases are mainly present at endometrial epithelia, both luminal and glandular, and that their expression fluctuates along the cycle and also changes after menopause. An important result was identifying NPP3 as a new biological marker of tubal metaplasia. Our results emphasize the relevance of the study of purinergic signaling in human fertility.
European Journal of Obstetrics & Gynecology and Reproductive Biology | 2015
Amparo García-Tejedor; Marta Castellarnau; Jordi Ponce; MªEulalia Fernández; Fernando Burdio
OBJECTIVE To study if ultrasound-guided aspiration with ethanol sclerosis is a safe and effective treatment for endometriomas. STUDY DESIGN We conducted a prospective study of 25 women with 27 endometriomas (two bilateral) measuring 4-10cm in diameter with no suspected malignancy, who underwent ultrasound-guided aspiration and ethanol sclerosis between August 2010 and July 2014. Patients were followed up by ultrasound at 6, 12, 24, and 36 months to identify rates of complication and recurrence. Clinical characteristics of the patients (age, history of infertility, previous surgery, and abdominal pain), the cysts (location, diameter, and volume) and the procedure (duration and complications) were recorded. Kaplan-Meier survival curves were used to analyze the recurrence rates by SPSS statistical software. RESULTS The recurrence rate after sclerosis was 12%. The mean length of follow-up was 17 (SD 9.9) months. Although no major procedure-related complications were recorded, minor complications included three cases of low abdominal pain during the procedure (10.7%) and two cases of abdominal ethanol extravasation (7.1%). CONCLUSION Ultrasound-guided aspiration and ethanol sclerotherapy are a safe and effective treatment for endometriomas measuring 4-10cm in diameter with no evidence of malignancy. This conservative treatment could possibly achieve a symptomatic cure while preserving healthy ovarian tissue, thereby improving fertility outcomes and avoiding early menopause.
Radiotherapy and Oncology | 2018
David Cibula; Richard Pötter; François Planchamp; Elisabeth Åvall-Lundqvist; D. Fischerova; Christine Haie Meder; Christhardt Köhler; Fabio Landoni; Sigurd Lax; Jacob Christian Lindegaard; Umesh Mahantshetty; Patrice Mathevet; W. Glenn McCluggage; Mary McCormack; Raj Naik; Remi A. Nout; Sandro Pignata; Jordi Ponce; Denis Querleu; Francesco Raspagliesi; Alexandros Rodolakis; Karl Tamussino; Pauline Wimberger; Maria Rosaria Raspollini
BACKGROUND Despite significant advances in the screening, detection, and treatment of preinvasive cervical lesions, invasive cervical cancer is the fifth most common cancer in European women. There are large disparities in Europe and worldwide in the incidence, management, and mortality of cervical cancer. OBJECTIVE The European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly develop clinically relevant and evidence-based guidelines in order to improve the quality of care for women with cervical cancer across Europe and worldwide. METHODS The ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of cervical cancer (23 experts across Europe). To ensure that the guidelines are evidence based, the current literature identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 159 international reviewers, selected through ESGO/ESTRO/ESP and including patient representatives. RESULTS The guidelines cover comprehensively staging, management, and follow-up for patients with cervical cancer. Management includes fertility sparing treatment; stage T1a, T1b1/T2a1, clinically occult cervical cancer diagnosed after simple hysterectomy; early and locally advanced cervical cancer; primary distant metastatic disease; cervical cancer in pregnancy; and recurrent disease. Principles of radiotherapy and pathological evaluation are defined.
International Journal of Molecular Sciences | 2017
Elisenda Alsina-Sanchís; Agnès Figueras; Álvaro Lahiguera; Marta Gil-Martin; Beatriz Pardo; Josep M. Piulats; Lola Martí; Jordi Ponce; Xavier Matias-Guiu; August Vidal; Alberto Villanueva; Francesc Viñals
There have been no major improvements in the overall survival of ovarian cancer patients in recent decades. Even though more accurate surgery and more effective treatments are available, the mortality rate remains high. Given the differences in origin and the heterogeneity of these tumors, research to elucidate the signaling pathways involved is required. The Transforming Growth Factor (TGFβ) family controls different cellular responses in development and cell homeostasis. Disruption of TGFβ signaling has been implicated in many cancers, including ovarian cancer. This article considers the involvement of TGFβ in ovarian cancer progression, and reviews the various mechanisms that enable the TGFβ signaling pathway to control ovarian cancer cell proliferation. These mechanistic explanations support the therapeutic use of TGFβ inhibitors in ovarian cancer, which are currently in the early phases of development.
Journal of Ultrasound in Medicine | 2015
Amparo García-Tejedor; Marta Castellarnau; Fernando Burdio; Eulalia Fernández; Dolores Martí; Maria J. Pla; Jordi Ponce
The purpose of this study was to establish the viability of ultrasound (US)‐guided adnexal cyst aspiration and identify a target group in which this procedure would be advisable.
Virchows Archiv | 2018
David Cibula; Richard Pötter; François Planchamp; Elisabeth Åvall-Lundqvist; D. Fischerova; Christine Haie-Meder; Christhardt Köhler; Fabio Landoni; Sigurd Lax; Jacob Christian Lindegaard; Umesh Mahantshetty; Patrice Mathevet; W. Glenn McCluggage; Mary McCormack; Raj Naik; Remi A. Nout; Sandro Pignata; Jordi Ponce; Denis Querleu; Francesco Raspagliesi; Alexandros Rodolakis; Karl Tamussino; Pauline Wimberger; Maria Rosaria Raspollini
Background:Despite significant advances in the screening, detection, and treatment of preinvasive cervical lesions, invasive cervical cancer is the fifth most common cancer in European women. There are large disparities in Europe and worldwide in the incidence, management, and mortality of cervical cancer.Objective:The European Society of Gynecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly develop clinically relevant and evidence-based guidelines in order to improve the quality of care for women with cervical cancer across Europe and worldwide.Methods:The ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of cervical cancer (23 experts across Europe). To ensure that the guidelines are evidence based, the current literature identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 159 international reviewers, selected through ESGO/ESTRO/ESP and including patient representatives.Results:The guidelines cover comprehensively staging, management, and follow-up for patients with cervical cancer. Management includes fertility sparing treatment; stage T1a, T1b1/T2a1, clinically occult cervical cancer diagnosed after simple hysterectomy; early and locally advanced cervical cancer; primary distant metastatic disease; cervical cancer in pregnancy; and recurrent disease. Principles of radiotherapy and pathological evaluation are defined.
Archives of Gynecology and Obstetrics | 2018
Peter Rusch; Rainer Kimmig; F. Lecuru; Jan Persson; Jordi Ponce; Michel Degueldre; R.H. Verheijen
PurposeTo set forth experiences in the context of the SERGS Pilot Curriculum—the first standardized educational program for robotic use in gynecological surgery—in terms of feasibility, effectiveness and potential for certification.MethodsThe Society of European Robotic Gynecological Surgery (SERGS) outlined a Pilot Curriculum for standardized education in robot-assisted laparoscopic gynecological surgery. Its feasibility and acceptance were checked in the form of a fellowship pilot program conducted at four European Centers of Excellence for robot-assisted surgery. Results and conclusions derived from this pilot program are presented.ResultsThe SERGS Pilot Curriculum defines criteria for a standardized training and assessment of performance, boosts the learning curve of the candidate and increases contentment at work. Regarding face validity, it proves valuable as finally all candidates could perform the outlined procedure safely and efficiently without supervision.ConclusionDue to the immense increase of robotic procedures in gynecology standardized training curricula are indispensable. This seems highly necessary to ensure patients’ safety and surgical outcome. The SERGS Pilot Curriculum sets standards for a stepwise theoretical and practical training in gynecological robotic procedures. It seems feasible as instrument for accreditation as gynecologic robotic surgeon. Though as a general applicable guideline for systematic training in robot-assisted surgery, a definite curriculum should have a more definite timeline and implementation of a structured assessment of performance.
Clinical Breast Cancer | 2017
Sergi Fernandez-Gonzalez; Catalina Falo; Maria Pla; Sonia Pernas; Maite Bajen; Teresa Soler; Raul Ortega; Cecilia Quetglas; Xavier Perez-Martin; Maria Eulalia Fernandez Montoli; Miriam Campos; Mar Varela-Rodriguez; Jordi Ponce; Amparo García-Tejedor
Micro‐Abstract The clinical consequence of performing sentinel lymph node biopsy (SLNB) before or after neoadjuvant therapy (NAT) in breast cancer patients remains under study. Therefore, we present a comparison between both approaches. The lymphadenectomy rate is reduced by threefold when the SLNB is assessed after NAT with no increase in early recurrences; consequently, it seems that this approach has more advantages for the patients than before NAT. Background: In patients with breast cancer who are candidates for neoadjuvant therapy (NAT), the timing of when to perform sentinel lymph node biopsy (SLNB) remains under discussion. The aim of this study was to compare the advantages and disadvantages of SLNB performed before and after NAT. Patients and Methods: One hundred seventy‐two patients, T1c to T3 and N0 (clinically and according to ultrasound) candidates for NAT were included. We compared the outcomes of 2 groups: (1) 122 patients of whom SLNB was performed before NAT (pre‐NAT) from December 2006 to April 2014; and (2) 50 patients with SLNB performed after NAT (post‐NAT) from May 2014 to July 2016. Results: Both groups were homogeneous in baseline patient characteristics. The SLNB was positive in 50 patients [41.7%] (33 macrometastases [66%] and 17 micrometastases [34%]) versus 6 patients [12%] (5 macrometastases [83.3%] and 1 micrometastases [16.7%]) in pre‐ and post‐NAT groups, respectively. The lymphadenectomy was performed in 34 patients [28.3%] versus 4 patients [8%], with an odds ratio of 3.48 (95% confidence interval, 1.3‐9.3). The recurrences in the pre‐NAT group after a median follow‐up of 62 months were 12 systemic, 2 local and systemic, and none axillary. In the post‐NAT group were no recurrences after a median follow‐up of 16 months. Finally, SLNB after NAT reduces the delay in starting NAT from 24 to 14 days (medians; P < .001) and the identification of the SLNB was in 122 patients [100%] versus 49 patients [98%]. Conclusion: SLNB performed after NAT significantly reduces the rate of lymphadenectomies without any increase in recurrences at early follow‐up. Furthermore, it allows systemic treatment to be started earlier without interfering in the SLNB identification rate.
Journal of Minimally Invasive Gynecology | 2016
Marta Castellarnau; Amparo García-Tejedor; Ramon Carreras; Enric Cayuela; Jordi Ponce
STUDY OBJECTIVES To compare the efficacy of ultrasound-guided aspiration versus aspiration with ethanol sclerotherapy in the management of simple adnexal cysts measuring 3 to 10 cm, and to explore the risk factors for recurrence associated with each approach. DESIGN A prospective follow-up of patients after cyst aspiration with and without ethanol sclerotherapy in simple adnexal cysts in a single-center trial (Canadian Task Force classification II-1). SETTING Bellvitge Teaching Hospital, Barcelona, Spain. PATIENTS Cyst aspiration and ethanol sclerotherapy were performed in 66 and 75 patients, respectively, between 2002 and 2014. Women enrolled before March 2009 underwent simple aspiration (group 1), and those enrolled after March 2009 underwent ethanol sclerotherapy (group 2). INTERVENTIONS Ultrasound-guided fine-needle aspiration with and without ethanol sclerotherapy. MEASUREMENTS AND MAIN RESULTS Potential risk factors for recurrence-age, menopausal status, symptoms, cyst diameter, laterality, aspirated volume, simple US-guided aspiration or alcohol sclerotherapy, and complications-were analyzed by logistic regression. The recurrence rates were analyzed by the Kaplan-Meier and Mantel-Haenszel methods. The overall recurrence rates were 72.7% (48 of 66) in group 1 and 22.7% (17 of 75) in group 2 (p < .0001). Risk factors significantly associated with recurrence were simple aspiration without ethanol sclerotherapy (odds ratio [OR], 19.7; 95% confidence interval [CI], 6.756-57.714), postmenopausal status (OR, 9.3; 95% CI, 1.720-50.956), and cyst size (OR, 1.04; 95% CI, 1.005-1.093). CONCLUSION Based on the lower recurrence rate, ethanol sclerotherapy was more efficacious than simple aspiration in the management of simple adnexal cysts measuring <10 cm.